# The IRIS-HIV assay, a point-of-care, multiplex serological assay to identify HIV Infection and Vaccine-Induced Seropositivity

> **NIH NIH N43** · INTUITIVE BIOSCIENCES, INC. · 2022 · $299,855

## Abstract

Development of Diagnostics to Differentiate HIV Infection from Vaccine Induced Seropositivity: Several years of clinical trials have revealed that some HIV vaccines can elicit long-lasting (>15 years) serological immune responses that can be confused with HIV infection in common diagnostic tests. This phenomenon is known as vaccine-induced sero-reactivity or sero-positivity (VISR/VISP). The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to VISP, with high sensitivity and specificity.

## Key facts

- **NIH application ID:** 10667353
- **Project number:** 75N93022C00030-0-9999-1
- **Recipient organization:** INTUITIVE BIOSCIENCES, INC.
- **Principal Investigator:** KIMBERLY LUKE
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $299,855
- **Award type:** —
- **Project period:** 2022-07-01 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10667353

## Citation

> US National Institutes of Health, RePORTER application 10667353, The IRIS-HIV assay, a point-of-care, multiplex serological assay to identify HIV Infection and Vaccine-Induced Seropositivity (75N93022C00030-0-9999-1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10667353. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*